BHVN — Biohaven Ltd.

—
NYSE · Health Care · Pharmaceuticals · CIK 1935979 ·
Last close
$13.24
Market Cap
$2.00B
52W High
$18.24
52W Low
$8.03
ADV30
3,184,993
Next earnings
2026-10-29

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -126,420,000 -129,279,000 263,676,000 95,754,000 361,923,000
Jun 2026 0 — -124,899,000 -137,311,000 370,739,000 238,033,000 358,517,000
Mar 2026 0 — -130,428,000 -130,532,000 466,406,000 273,074,000 336,906,000
Dec 2025 0 — -142,734,000 -145,555,000 451,447,000 229,957,000 399,375,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-511,395,000
Investing CF
$211,262,000
Financing CF
$371,730,000
CapEx
$-715,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.64
As of
2026-11-01

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,352,379,000
Inventory
—
Receivables
—
ST Investments
$29,833,000
EBIT TTM
$-567,443,000
Pretax Income TTM
$-585,606,000
Interest Exp TTM
—
Analysts
15

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -745,378,000 -738,822,000 451,447,000 399,375,000 52,072,000 -609,438,000
Dec 2024 0 -885,111,000 -846,422,000 615,107,000 191,671,000 423,436,000 -582,453,000
Dec 2023 0 -436,051,000 -408,168,000 513,212,000 85,237,000 427,975,000 -331,725,000
Dec 2022 0 -567,932,000 -570,279,000 661,783,000 123,012,000 538,771,000 -297,689,000

TTM Snapshot

Revenues TTM
$663,422,000
NetIncome TTM
$-586,841,000
OpCashFlow TTM
—
Assets (Latest)
$370,739,000
Forward EPS
$-1.79

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $15.00 · spot: $12.90 · call volume: 3,086 · put volume: 176
Expected Move to 2026-12-18: ±$2.84 (22.02%) — implied range $10.06 – $15.74 · ATM straddle on $12.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
IMNM Immunome Inc. $2.03B $17.18 —
HRMY Harmony Biosciences Holdings, Inc. $1.94B $33.01 —
AUPH Aurinia Pharmaceuticals Inc. $2.06B $15.40 —
TRVI Trevi Therapeutics, Inc. $1.93B $13.51 —
SEPN Septerna, Inc. $1.90B $40.02 —

News headlines (Yahoo Finance, 1h cache)

Could Graves Data Alter The Investment Case For Biohaven (BHVN)?
2026-11-14 01:12 · Yahoo
Biohaven Drives New Research in Graves' Disease: Phase 3 Pivotal Trial with BHV-1300 Underway and Three Scientific Posters at the 2026 American Thyroid Association Annual (ATA) Meeting
2026-11-05 12:30 · Yahoo
Is Biohaven (BHVN) Undervalued After Its Narrower Loss And BHV 1420 Data?
2026-10-30 15:10 · Yahoo
Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results
2026-10-29 20:02 · Yahoo
Wall Street Analysts Believe Biohaven Ltd. (BHVN) Could Rally 43.49%: Here's is How to Trade
2026-10-29 12:55 · Yahoo
JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight
2026-10-26 14:31 · Yahoo
Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy
2026-10-26 11:30 · Yahoo
Biohaven Could Transform With Troriluzole's FDA Approval, RBC Says
2026-10-23 15:56 · Yahoo
Why Biohaven (BHVN) Is Up 25.0% And What's Next After FDA Review Acceptance
2026-10-23 11:18 · Yahoo
Biohaven (BHVN) Soars 25% on FDA Drug Review, Price Target Upgrade
2026-10-23 02:28 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.